| HRA002727
(Controlled Access)
|
It is increasingly important for clinicians involved in the management of prostate cancer to understand the relevance of acquired (somatic) mutations that occur in prostate cancer cells. In the advanced disease setting, mutations in homologous recombination repair genes (eg, BRCA1, BRCA2, ATM, CHEK2, PALB2) suggest candidacy for platinum chemotherapy and PARP inhibitor trials. Similarly, microsatellite instability and mismatch repair deficiency, which may arise in the setting of MLH1, MSH2, MSH6, and PMS2 mutations, suggest potential vulnerability to PD-1 inhibitors. Tumor-directed somatic sequencing may guide treatment decision-making.Here, we sequenced Prostate Cancer Patients in 1,016 Chinese patients .Somatic DNA was sequenced using a multigene panel, Clinical characteristics were assessed by mutation status. |
